Analysts Cuts Leave UBS Off an IPO

Santini, Laura
September 2003
Investment Dealers' Digest;9/8/2003, Vol. 69 Issue 34, p9
Trade Publication
Reports that UBS AG has been eliminated from the list of investment banks for Aderis Pharmaceuticals Inc.'s initial public offering. Lay-off of UBS biotechnology analysts; Importance of research coverage for chief financial officers; Aderis' line of business.


Related Articles

  • Will that IPO soar to the moon--or fizzle back to earth? Mangan, Doreen // Medical Economics;07/10/2000, Vol. 77 Issue 13, p50 

    Evaluates whether the trend of securing venture capital through launch of initial public offering (IPO) in the United States will continue. Role of the Internet in increasing the popularity of the said strategy; Web sites offering information about IPO; Tips on making investments in IPO. ...

  • Rightmove prepares for possible IPO. Biesterfield, Caroline // Mortgage Strategy;8/15/2005, p6 

    Reports that online property site, Rightmove, has appointed UBS to work on a potential initial public offering. Estimated value of the site; Shareholders of the site.

  • A Structural View of Value. DeGraw, Irv // On Wall Street;Mar2001, Vol. 11 Issue 3, p101 

    Examines the structural factors in the securities industry which influence the valuation of an initial public offering (IPO). Influence of stockbrokers on the valuation of an IPO; Significance of analyst coverage in IPO valuations; Responsibilities of the lead underwriter.

  • Natus finishes $84M offering; SafeStitch in $4M stock sale.  // Diagnostics & Imaging Week;6/5/2008, Vol. 11 Issue 23, p5 

    The article reports on the completion of a public offering of 4.6 million shares of common stock by Natus Medical. The stocks are priced at $19.50 per share. Net proceeds from the offering will be received by Natus Medical including the sale of the over-allotment shares estimated at $84.3...

  • Astron mulls IPO.  // Printing World;11/25/2004, Vol. 288 Issue 10, p6 

    The article briefly reports on business planning of document management and business process specialist firm Astron Ltd. Swiss bank UBS AG has been appointed to explore options for the future of Astron. Together with major backer PPM Ventures Ltd., Astron has never made any secret that an IPO...

  • Financings roundup.  // Diagnostics & Imaging Week;11/29/2007, Vol. 10 Issue 48, p3 

    The article reports on the closure of the initial public offering (IPO) of Inverness Medical Innovations (IMI) on November 20, 2007. IMI sold its shares at $61.49 a share. Net proceeds to IMI were estimated at $806.4 million. Joint book-running managers for the offering are UBS Investment Bank,...

  • BioMed Realty public offering with UBS to gross $403 million.  // Medical Device Daily;11/15/2011, Vol. 15 Issue 219, p3 

    The article discusses the public offering of 22, 562, 922 shares of BioMed Realty Trust common stock by UBS Investment Bank, the sole underwriter. The price was indicated to be at 17.92 dollars per share and with gross proceeds expected to reach 404.3 million dollars. HealthStream's public...

  • With Pralatrexate at the FDA, Allos Prices Public Offering.  // BioWorld Today;4/1/2009, Vol. 20 Issue 61, p5 

    The article reports on the efforts of Allos Therapeutics Inc. to boost its cash reserves with a public offering in 2009. According to the company, it had priced an offering of 7.75 million shares of common stock. The sole manager for the offering is UBS Investment Bank. It is noted that the...

  • Taking the Pulse of Equities. Rozens, Aleksandrs // Investment Dealers' Digest;3/25/2011, Vol. 77 Issue 12, p1 

    An interview with Mary Ann Deignan, UBS AG's head of equity capital markets in the U.S., is presented. When asked regarding the condition of U.S. equity markets in March 2011, given the tragedy in Japan, she says that there were initial public offerings (IPOs) that were drawn back, which means...


Read the Article


Sign out of this library

Other Topics